PharmNovo

Sweden
Lund, Skane Lan, Sweden
+46 (0)705 44 32 50 ★

Company profile

PharmNovo company profile

PharmNovo's goal is to develop novel Delta Opioid Receptor Agonists that are safe and effective for chronic pain treatment (DORAs). This is a very different target than traditional opioid drugs, which have caused an epidemic of addiction and toxicity. The company addresses the significant unmet medical need for safe and effective chronic pain treatments, which affects up to 30% of the adult population in the United States and Europe.

Business identity

Contact email
[email protected]
Phone number
+46 (0)705 44 32 50
Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Revenue range
$1K+
Founded
2008-01-01

Headquarters

Headquarters
Lund, Skane Lan, Sweden
Postal code
SE223 81
Country code
SE
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
6
Total equity funding
$28.4M
Last funding
Series Unknown / $16.3M / 2024-07-15
Last equity funding
Series Unknown / $16.3M
Investors
5
Lead investors
2
Founders
1
Articles
22

Founders and investors

Founders

Bengt Mentzer

Lead investors

EIC AcceleratorSciety

Investors

Almi InvestEIC AcceleratorKarolinskaPolynom InvestmentSciety

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.